Supplemental Digital Content 4. Reasons for Snapshot Non-response in the Subgroup of Participants With Baseline CD4+ Cell Count ≤200 Cells/mm^3 at Week 144

Participants, n (%)	DTG + 3TC (N=63)	DTG + TDF/FTC (N=55)
Snapshot non-response	21 (33)	13 (24)
Protocol-defined confirmed virologic withdrawal	3 (5)[a]	0[b]
HIV-1 RNA ≥50 copies/mL and completed the study	0	1 (2)
Discontinued because of treatment-related AE	1 (2)	1 (2)
Discontinued because of non–treatment-related AE	4 (6)	0
Protocol violation (eligibility criteria not met)	2 (3)	0
Lost to follow-up	4 (6)	5 (9)
Withdrew consent	4 (6)	4 (7)
Withdrew to start HCV treatment	1 (2)	0
Change in ART (due to incarceration)	1 (2)	0
Investigator discretion	0	2 (4)
Pregnancy	1 (2)	0

AE, adverse event; ART, antiretroviral therapy; DTG, dolutegravir; FTC, emtricitabine; HCV, hepatitis C virus; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate.

[a]Baseline viral loads for these 3 participants were 368,439, 112,812, and 63,817 copies/mL. [b]One participant (not included in table) met the criteria for confirmed virologic withdrawal at Week 12 but was not reported at the Week 48 analysis because of a laboratory reporting error identified after the Week 48 analysis. This participant was not withdrawn as per protocol and has been allowed to continue in the study (the participant has maintained virologic suppression from Week 24 through Week 132, met SVW criteria at Week 144, and re-suppressed upon re-testing).